

## List of Tables

<b>Table No.</b>	<b>Description</b>	<b>Page No.</b>
4.1	The intra-day and inter-day variability of the analytical method in water	68
4.2	The intra-day and inter-day variability of the analytical method in phosphate buffer pH 7.4	69
4.3	The intra-day and inter-day variability of the bioanalytical method	72
5.1	Experimental variables with their levels in Plackett-Burman screening design	79
5.2	Independent variables with their levels and dependent variables in Box-Behnken experimental design	81
5.3	Plackett-Burman screening design experimental matrix	99
5.4	Results of dependent variables obtained through Plackett-Burman design	100
5.5	Statistical analysis of dependent variables of Plackett–Burman screening design	102
5.6	Model summary statistics of the quadratic response surface models	103
5.7	Box-Behnken experimental design showing experimental runs with independent variables and their measured responses: particle size ( $Y_1$ ), encapsulation efficiency ( $Y_2$ ), and PDI ( $Y_3$ ) of CS-PNs	105
5.8	Statistical analysis of dependent variables of Box-Behnken experimental design along with estimated regression coefficients and associated $p$ values	106
5.9	Statistical analysis results of lack of fit for particle size, EE and PDI of CS-PNs	107
5.10	Comparison of experimental and predicted values of optimized CS-PNs with its desirability generated by Design expert <sup>®</sup>	116
5.11	<i>In-vitro</i> drug release data of the optimized CS-PNs in phosphate buffer pH 7.4	124

5.12	Release kinetic models for simulation of release behaviour of CS from optimized CS-PNs in phosphate buffer pH 7.4	125
5.13	<i>Ex-vivo</i> permeation data of the CS solution and optimized CS-PNs across rat intestinal membrane.	129
5.14	Plasma drug concentration time profile data of CS solution and CS-PNs following single dose oral administration in rats.	133
5.15	Pharmacokinetic parameters of CS and CS-PNs following single oral administration in rats (Dose: 20 mg/kg)	134
5.16	Effect of oral administration of CS solution and CS-PNs on compound 48/80 induced degranulation of peritoneal mast cells and histamine release in rats (Dose: 20 mg/kg)	137
6.1	Experimental variables with their levels in Plackett-Burman screening design	141
6.2	Independent variables with their levels and dependent variables in Box-Behnken experimental design	143
6.3	Plackett-Burman screening design experimental matrix	156
6.4	Results of dependent variables obtained through Plackett-Burman design	157
6.5	Statistical analysis of dependent variables of Plackett-Burman screening design	159
6.6	Model summary statistics of the quadratic response surface models	160
6.7	Box-Behnken experimental design showing experimental runs with independent variables and their measured responses: particle size ( $Y_1$ ), encapsulation efficiency ( $Y_2$ ), and PDI ( $Y_3$ ) of CS-SLNs	162
6.8	Statistical analysis of dependent variables of Box-Behnken experimental design along with estimated regression coefficients and associated $p$ values	163
6.9	Statistical analysis results of lack of fit for particle size, EE and PDI of CS-PNs	165
6.10	Comparison of experimental and predicted values of optimized CS-SLNs with its desirability generated by Design expert <sup>®</sup>	174

6.11	<i>In-vitro</i> drug release data of the optimized CS-SLNs in phosphate buffer pH 7.4	182
6.12	Release kinetic models for simulation of release behaviour of CS from optimized CS-SLNs in phosphate buffer pH 7.4	183
6.13	<i>Ex-vivo</i> permeation data of the CS solution and optimized CS-SLNs across rat intestinal membrane	187
6.14	Plasma drug concentration time profile data of CS solution and CS-SLNs following single dose oral administration in rats	191
6.15	Pharmacokinetic parameters of CS and CS-SLNs following single oral administration in rats (Dose: 20 mg/kg)	192
6.16	Effect of oral administration of CS solution and CS-SLNs on compound 48/80 induced degranulation of peritoneal mast cells and histamine release in rats (Dose: 20 mg/kg)	194
7.1	Experimental variables with their levels in Plackett-Burman screening design	200
7.2	Independent variables with their levels and dependent variables in Box-Behnken experimental design	201
7.3	Plackett-Burman screening design experimental matrix	211
7.4	Results of dependent variables obtained through Plackett-Burman design	212
7.5	Statistical analysis of dependent variables of Plackett-Burman screening design	215
7.6	Model summary statistics of the quadratic response surface models	216
7.7	Box-Behnken experimental design showing experimental runs with independent variables and their measured responses: particle size ( $Y_1$ ), encapsulation efficiency ( $Y_2$ ), and PDI ( $Y_3$ ) of CS-PLHNs	218
7.8	Statistical analysis of dependent variables of Box-Behnken experimental design along with estimated regression coefficients and associated $p$ values	219
7.9	Statistical analysis results of lack of fit for particle size, EE and PDI of CS-PLHNs	221

7.10	Comparison of experimental and predicted values of optimized CS-PLHNs with its desirability generated by Design expert <sup>®</sup>	231
7.11	<i>In-vitro</i> drug release data of the optimized CS-PLHNs in phosphate buffer pH 7.4	241
7.12	Release kinetic models for simulation of release behaviour of CS from optimized CS-PLHNs in phosphate buffer pH 7.4	243
7.13	<i>Ex-vivo</i> permeation data of the CS solution and optimized CS-PLHNs across rat intestinal membrane	247
7.14	Plasma drug concentration time profile data of CS solution and CS-PLHNs following single dose oral administration in rats.	251
7.15	Pharmacokinetic parameters of CS and CS-PLHNs following single dose oral administration in rats (Dose: 20 mg/kg)	253
7.16	Effect of oral administration of CS solution and CS-PLHNs on compound 48/80 induced degranulation of peritoneal mast cells and histamine release in rats (Dose: 20 mg/kg)	255
8.1	Experimental variables with their levels in Plackett-Burman screening design	261
8.2	Independent variables with their levels and dependent variables in Box-Behnken experimental design	263
8.3	Plackett-Burman screening design experimental matrix	273
8.4	Results of dependent variables obtained through Plackett-Burman design	274
8.5	Statistical analysis of dependent variables of Plackett-Burman screening design	276
8.6	Model summary statistics of the quadratic response surface models	277
8.7	Box-Behnken experimental design showing experimental runs with independent variables and their measured responses: particle size ( $Y_1$ ), encapsulation efficiency ( $Y_2$ ), and PDI ( $Y_3$ ) of CS-PCCSNs	280
8.8	Statistical analysis of dependent variables of Box-Behnken experimental design along with estimated regression coefficients and associated $p$ values	281

8.9	Statistical analysis results of lack of fit for particle size, EE and PDI of CS-PCCSNs	282
8.10	Comparison of experimental and predicted values of optimized CS-PCCSNs with its desirability generated by Design expert <sup>®</sup>	291
8.11	<i>In-vitro</i> drug release data of the optimized CS-PCCSNs in phosphate buffer pH 7.4	302
8.12	Release kinetic models for simulation of release behaviour of CS from optimized CS-PCCSNs in phosphate buffer pH 7.4	304
8.13	<i>Ex-vivo</i> permeation data of the CS solution and optimized CS-PCCSNs across rat intestinal membrane	307
8.14	Plasma drug concentration time profile data of CS solution and CS-PCCSNs following single dose oral administration in rats	311
8.15	Pharmacokinetic parameters of CS and CS-PCCSNs following single dose oral administration in rats (Dose: 20 mg/kg)	313
8.16	Effect of oral administration of CS solution and CS-PCCSNs on compound 48/80 induced degranulation of peritoneal mast cells and histamine release in rats (Dose: 20 mg/kg)	316
9.1	Comparative EE (%) of different optimized nanocarrier systems	319
9.2	Comparative <i>in-vitro</i> drug release data of the optimized nanocarriers in phosphate buffer pH 7.4	321
9.3	Comparative <i>ex-vivo</i> permeation data of the CS solution and different optimized CS encapsulated nanocarriers across rat intestine	323
9.4	Comparative apparent permeability coefficients (Papp) along with permeability enhancement ratio for CS-solution and different optimized nanocarriers across the rat intestinal tissue	324
9.5	Comparative plasma drug concentration time profile data of CS solution and different optimized CS encapsulated nanocarriers following single dose oral administration in rats	326
9.6	Comparative pharmacokinetic parameters of CS solution and different nanocarrier system following single dose oral administration in rats (Dose: 20 mg/kg)	328